KCM
ATYR

Kennedy Capital Management’s aTyr Pharma ATYR Stock Holding History

Kennedy Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,514
Closed -$109K – 621
2025
Q2 		$109K Buy
+21,514
New +$84.6K ﹤0.01% 579

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kennedy Capital Management's ATYR Position: Q3 2025 in Review

Kennedy Capital Management sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 21,514 shares — an estimated $109K sold.

Kennedy Capital Management first reported a position in ATYR in Q2 2025 and held it in 1 quarter. The position peaked at $109K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

  • Kennedy Capital Management reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 21,514 aTyr Pharma shares in Q3 2025, an estimated $109K.
  • Kennedy Capital Management first reported a position in aTyr Pharma in Q2 2025 and held it in 1 quarter.
  • Kennedy Capital Management's aTyr Pharma position peaked at $109K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Kennedy Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.